Literature DB >> 2970053

Total joint replacement: a consideration for antimicrobial prophylaxis.

G A Cioffi1, G T Terezhalmy, G M Taybos.   

Abstract

Infection is the principal and most devastating complication of total joint replacement, resulting in long periods of hospitalization, staggering costs, loss of the implant, disastrous physical impairment, and even death. Staphylococcus aureus and Staphylococcus epidermidis account for more than 50% of late infections. Animal studies have shown that joint implants are at a high risk of becoming infected via a metastatic hematogenous route during transient bacteremias. Because cephalosporins have been established as the perioperative and intraoperative agents of choice to prevent infections related to total joint replacement, oral cephalosporins are the drugs of choice to minimize the potential for the metastatic infection of prosthetic joints associated with transient dental bacteremias. Clindamycin is preferred for patients who are allergic to the cephalosporins or who may have a cross-allergy between penicillin and the cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2970053     DOI: 10.1016/0030-4220(88)90079-5

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol        ISSN: 0030-4220


  3 in total

1.  Antibiotic prophylaxis for haematogenous bacterial arthritis in patients with joint disease: a cost effectiveness analysis.

Authors:  P Krijnen; C J Kaandorp; E W Steyerberg; D van Schaardenburg; H J Moens; J D Habbema
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

2.  Group C streptococcal septic arthritis of a prosthetic hip joint following dental treatment.

Authors:  Sarah Al-Himdani; David Woodnutt
Journal:  BMJ Case Rep       Date:  2015-10-22

3.  Gentamicin coating of nanotubular anodized titanium implant reduces implant-related osteomyelitis and enhances bone biocompatibility in rabbits.

Authors:  Denghui Liu; Chongru He; Zhongtang Liu; Weidong Xu
Journal:  Int J Nanomedicine       Date:  2017-07-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.